Charles S Berkman Avista Public Acquisition Corp. Ii (AHPAW) insider trading activity

Charles S Berkman is Chief Legal Officer of Avista Public Acquisition Corp. II. Currently has a direct ownership of 363,212 shares of AHPAW, which is worth approximately $250,616. The most recent transaction as insider was on Apr 07, 2025, when has been sold 7,206 shares (Common Stock) at a price of $2.0 per share, resulting in proceeds of $14,412. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 363K

12.32% 3M change

24.13% 12M change

Total Value Held $250,616

Charles S Berkman Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 07 2025	SELL Open market or private sale	$14,412 $2.0 p/Share	7,206 Reduced 1.95%	363,212 Common Stock
Apr 07 2025	BUY Exercise of conversion of derivative security	-	13,542 Added 3.53%	370,418 Common Stock
Feb 19 2025	SELL Open market or private sale	$26,625 $3.67 p/Share	7,255 Reduced 1.99%	356,876 Common Stock
Feb 18 2025	SELL Open market or private sale	$30,231 $3.68 p/Share	8,215 Reduced 2.21%	364,131 Common Stock
Feb 16 2025	BUY Exercise of conversion of derivative security	-	13,541 Added 3.51%	372,346 Common Stock
Feb 15 2025	BUY Exercise of conversion of derivative security	-	15,615 Added 4.17%	358,805 Common Stock
Jan 21 2025	SELL Open market or private sale	$82,584 $3.24 p/Share	25,489 Reduced 6.91%	343,190 Common Stock
Jan 17 2025	BUY Grant, award, or other acquisition	-	45,294 Added 10.94%	368,679 Common Stock
Dec 09 2024	SELL Open market or private sale	$33,130 $4.13 p/Share	8,022 Reduced 2.42%	323,385 Common Stock
Dec 07 2024	BUY Exercise of conversion of derivative security	-	15,621 Added 4.5%	331,407 Common Stock
Apr 08 2024	SELL Open market or private sale	$36,647 $5.27 p/Share	6,954 Reduced 2.32%	292,617 Common Stock
Apr 07 2024	BUY Exercise of conversion of derivative security	-	13,541 Added 4.32%	299,571 Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$42,153 $5.54 p/Share	7,609 Reduced 2.59%	286,030 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	-	21,322 Added 6.89%	288,064 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$44,968 $6.25 p/Share	7,195 Reduced 2.57%	272,317 Common Stock
Jan 02 2024	BUY Exercise of conversion of derivative security	-	17,556 Added 5.91%	279,512 Common Stock
Dec 07 2023	SELL Payment of exercise price or tax liability	$26,204 $4.85 p/Share	5,403 Reduced 2.02%	261,956 Common Stock
Dec 07 2023	BUY Exercise of conversion of derivative security	-	15,622 Added 5.52%	267,359 Common Stock
Apr 07 2023	BUY Grant, award, or other acquisition	-	40,625 Added 8.92%	414,564 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$36,263 $3.8 p/Share	9,543 Reduced 2.49%	373,939 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	46,864 Added 10.89%	383,482 Common Stock
Dec 28 2022	SELL Payment of exercise price or tax liability	$23,855 $3.66 p/Share	6,518 Reduced 1.9%	336,618 Common Stock
Dec 01 2022	SELL Payment of exercise price or tax liability	$35,443 $3.35 p/Share	10,580 Reduced 2.99%	343,136 Common Stock
Nov 01 2022	BUY Grant, award, or other acquisition	-	353,716 Added 50.0%	353,716 Common Stock

Also insider at

LGND

LIGAND PHARMACEUTICALS INC Healthcare

CSB